208 related articles for article (PubMed ID: 19470512)
41. The Aspergillus fumigatus Damage Resistance Protein Family Coordinately Regulates Ergosterol Biosynthesis and Azole Susceptibility.
Song J; Zhai P; Zhang Y; Zhang C; Sang H; Han G; Keller NP; Lu L
mBio; 2016 Feb; 7(1):e01919-15. PubMed ID: 26908577
[TBL] [Abstract][Full Text] [Related]
42.
Chitty JL; Blake KL; Blundell RD; Koh YQAE; Thompson M; Robertson AAB; Butler MS; Cooper MA; Kappler U; Williams SJ; Kobe B; Fraser JA
J Biol Chem; 2017 Jul; 292(28):11829-11839. PubMed ID: 28559277
[TBL] [Abstract][Full Text] [Related]
43. Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii.
Morales IJ; Vohra PK; Puri V; Kottom TJ; Limper AH; Thomas CF
Am J Respir Cell Mol Biol; 2003 Aug; 29(2):232-8. PubMed ID: 12606318
[TBL] [Abstract][Full Text] [Related]
44. Molecular dynamic modeling of CYP51B in complex with azole inhibitors.
Gao P; Cui YL; Wu RL
J Biomol Struct Dyn; 2018 May; 36(6):1511-1519. PubMed ID: 28504057
[TBL] [Abstract][Full Text] [Related]
45. Identification of Y118 amino acid residue in Candida albicans sterol 14alpha-demethylase associated with the enzyme activity and selective antifungal activity of azole analogues.
Chen SH; Sheng CQ; Xu XH; Jiang YY; Zhang WN; He C
Biol Pharm Bull; 2007 Jul; 30(7):1246-53. PubMed ID: 17603162
[TBL] [Abstract][Full Text] [Related]
46. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals.
Hitchcock CA
Biochem Soc Trans; 1991 Aug; 19(3):782-7. PubMed ID: 1783216
[No Abstract] [Full Text] [Related]
47. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.
Marichal P; Koymans L; Willemsens S; Bellens D; Verhasselt P; Luyten W; Borgers M; Ramaekers FCS; Odds FC; Vanden Bossche H
Microbiology (Reading); 1999 Oct; 145 ( Pt 10)():2701-2713. PubMed ID: 10537192
[TBL] [Abstract][Full Text] [Related]
48. In silico analysis of cytochrome P450 monooxygenases in chronic granulomatous infectious fungus Sporothrix schenckii: Special focus on CYP51.
Matowane RG; Wieteska L; Bamal HD; Kgosiemang IKR; Van Wyk M; Manume NA; Abdalla SMH; Mashele SS; Gront D; Syed K
Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):166-177. PubMed ID: 28989052
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the combination mode of azoles antifungal inhibitors with CACYP51 and the influence of Site-directed mutation.
Sun B; Huang W; Liu M
J Mol Graph Model; 2017 May; 73():157-165. PubMed ID: 28282632
[TBL] [Abstract][Full Text] [Related]
50. An Erg11 lanosterol 14-α-demethylase-Arv1 complex is required for Candida albicans virulence.
Villasmil ML; Barbosa AD; Cunningham JL; Siniossoglou S; Nickels JT
PLoS One; 2020; 15(7):e0235746. PubMed ID: 32678853
[TBL] [Abstract][Full Text] [Related]
51. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
Sheng C; Zhang W; Ji H; Zhang M; Song Y; Xu H; Zhu J; Miao Z; Jiang Q; Yao J; Zhou Y; Zhu J; Lü J
J Med Chem; 2006 Apr; 49(8):2512-25. PubMed ID: 16610794
[TBL] [Abstract][Full Text] [Related]
52. cyp51A-based mechanism of azole resistance in Aspergillus fumigatus: Illustration by a new 3D Structural Model of Aspergillus fumigatus CYP51A protein.
Liu M; Zheng N; Li D; Zheng H; Zhang L; Ge H; Liu W
Med Mycol; 2016 May; 54(4):400-8. PubMed ID: 26768370
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of new antifungal peptides selective against Cryptococcus neoformans.
Grimaldi M; De Rosa M; Di Marino S; Scrima M; Posteraro B; Sanguinetti M; Fadda G; Soriente A; D'Ursi AM
Bioorg Med Chem; 2010 Nov; 18(22):7985-90. PubMed ID: 20943406
[TBL] [Abstract][Full Text] [Related]
54. Structural basis of human CYP51 inhibition by antifungal azoles.
Strushkevich N; Usanov SA; Park HW
J Mol Biol; 2010 Apr; 397(4):1067-78. PubMed ID: 20149798
[TBL] [Abstract][Full Text] [Related]
55. In silico and in vitro screening to identify structurally diverse non-azole CYP51 inhibitors as potent antifungal agent.
Singh A; Paliwal SK; Sharma M; Mittal A; Sharma S; Sharma JP
J Mol Graph Model; 2016 Jan; 63():1-7. PubMed ID: 26579619
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
Zhao S; Zhao L; Zhang X; Liu C; Hao C; Xie H; Sun B; Zhao D; Cheng M
Eur J Med Chem; 2016 Nov; 123():514-522. PubMed ID: 27494168
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
Xu J; Cao Y; Zhang J; Yu S; Zou Y; Chai X; Wu Q; Zhang D; Jiang Y; Sun Q
Eur J Med Chem; 2011 Jul; 46(7):3142-8. PubMed ID: 21420761
[TBL] [Abstract][Full Text] [Related]
58. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mast N; Zheng W; Stout CD; Pikuleva IA
Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
[TBL] [Abstract][Full Text] [Related]
59. A newly identified amino acid substitution T123I in the 14α-demethylase (Erg11p) of Candida albicans confers azole resistance.
Wu Y; Gao N; Li C; Gao J; Ying C
FEMS Yeast Res; 2017 May; 17(3):. PubMed ID: 28334124
[TBL] [Abstract][Full Text] [Related]
60. Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.
Sagatova AA; Keniya MV; Wilson RK; Monk BC; Tyndall JD
Antimicrob Agents Chemother; 2015 Aug; 59(8):4982-9. PubMed ID: 26055382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
